查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1702511

囊状纤维化症治疗的全球市场的评估:各类药物，各给药途径，各流通管道，各地区，机会，预测(2018年～2032年)

Cystic Fibrosis Therapeutics Market Assessment, By Drug Class, By Route of Administration, By Distribution Channel, By Region, Opportunities and Forecast, 2018-2032F
出版日期: | 出版商: Market Xcel - Markets and Data | 英文 230 Pages | 商品交期: 3-5个工作天内

价格

全球囊性纤维化治疗市场规模预计将从 2024 年的 136.1 亿美元增长到 2032 年的 407.6 亿美元，预测期内（2025-2032 年）的复合年增长率为 14.70%。市场的成长得益于各地区囊性纤维化负担的增加、各个监管机构的批准增加以及普通人群对囊性纤维化症状的认识提高。囊性纤维化基金会估计，美国每年诊断出约 1,000 例囊性纤维化新病例，其中超过 75% 的病例是在患者 2 岁之前诊断出来的。

此外，快速引入创新疗法和增加临床试验以扩大患者群正在为市场提供有利可图的成长机会。囊性纤维化会损害电解质运输系统，因此细胞开始保留水和钠，加剧黏液腺和出汗问题。因此，囊性纤维化患者极易出现慢性咳嗽、肺部塌陷、咳血和呼吸道感染。因此，领先的医疗机构和製药公司越来越注重开发治疗方案来应对日益严重的威胁。製药公司正大力投资研发活动，以推出标靶疗法、联合疗法、基因编辑技术等。

支持性健康政策（包括孤儿药指定和报销框架）正在改善获得先进疗法的机会。另一方面，非营利组织不断加强的宣传活动和政府透过扩大新生儿筛检计画来提高早期诊断率的措施正在推动市场需求。

本报告提供全球囊状纤维化症治疗市场相关调查分析，提供市场规模与预测，市场动态，主要企业形势等资讯。

目录

第1章 计划的范围和定义

第2章 调查手法

第3章 摘要整理

第4章 全球囊状纤维化症治疗市场预测(2018年～2032年)

  • 市场规模分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各类药物
    • 各给药途径
    • 各流通管道
    • 各地区
    • 市场占有率分析:各企业(金额)(前五名公司和其他 - 2024年)
  • 市场地图分析(2024年)
    • 各类药物
    • 各给药途径
    • 各流通管道
    • 各地区

第5章 北美的囊状纤维化症治疗市场预测(2018年～2032年)

  • 市场规模分析与预测
    • 金额
  • 市场占有率的分析与预测
    • 各类药物
    • 各给药途径
    • 各流通管道
    • 占有率:各国
  • 各国的市场评估
    • 美国的囊状纤维化症治疗市场预测(2018年～2032年)
    • 加拿大
    • 墨西哥

第6章 欧洲的囊状纤维化症治疗市场预测(2018年～2032年)

  • 德国
  • 法国
  • 义大利
  • 英国
  • 俄罗斯
  • 荷兰
  • 西班牙
  • 土耳其
  • 波兰

第7章 亚太地区的囊状纤维化症治疗市场预测(2018年～2032年)

  • 印度
  • 中国
  • 日本
  • 澳洲
  • 越南
  • 韩国
  • 印尼
  • 菲律宾

第8章 南美的囊状纤维化症治疗市场预测(2018年～2032年)

  • 巴西
  • 阿根廷

第9章 中东·非洲的囊状纤维化症治疗市场预测(2018年～2032年)

  • 沙乌地阿拉伯
  • 阿拉伯联合大公国
  • 南非

第10章 供需分析

第11章 价值链分析

第12章 波特的五力分析

第13章 大环境分析

第14章 价格分析

第15章 市场动态

  • 推动市场要素
  • 市场课题

第16章 市场趋势与发展

第17章 法规形势

第18章 临床试验概要

第19章 案例研究

第20章 竞争情形

  • 前五名市场领导者的竞争矩阵
  • 前五名公司的SWOT分析
  • 主要企业前十大企业的形势
    • AbbVie Inc.
    • Gilead Sciences, Inc.
    • Novartis AG
    • Vertex Pharmaceuticals Incorporated
    • Alaxia S.A.S.
    • Teva Pharmaceutical Industries Ltd.
    • Merck & Co. Inc.
    • F. Hoffmann-La Roche Ltd
    • Mylan NV
    • AstraZeneca plc

第21章 策略性建议

第22章 关于调查公司·免责声明

Product Code: MX12948

Global cystic fibrosis therapeutics market is projected to witness a CAGR of 14.70% during the forecast period 2025-2032, growing from USD 13.61 billion in 2024 to USD 40.76 billion in 2032. The market's growth is supported by the increasing burden of cystic fibrosis in different regions, rising approvals from different regulatory bodies, and growing awareness about the condition among the general population. According to the estimates of the Cystic Fibrosis Foundation, about 1,000 new cases of cystic fibrosis are diagnosed each year in the United States, with over 75% of the cases being diagnosed by the time the patient is 2 years old.

Additionally, the rapid introduction of innovative therapies along with the growing number of clinical trials to expand the patient base are further providing lucrative growth opportunities for the market. Cystic fibrosis impairs the electrolyte transport system, because of which cells start retaining water and sodium, exacerbating issues related to mucus-producing glands and sweat. Thus, patients suffering from cystic fibrosis are highly susceptible to chronic coughs, lung collapses, hemoptysis, and respiratory infections, among others. Therefore, leading healthcare organizations and pharmaceutical companies are increasingly focusing on developing therapeutic solutions to combat the growing threat of the condition. The pharmaceutical companies are investing heavily in research and development activities to introduce targeted therapies, combination treatments, and gene editing technologies, among others.

Supportive healthcare policies, including orphan drug designations and reimbursement frameworks are enhancing accessibility to advanced therapies. Meanwhile, increasing awareness campaigns by nonprofit organizations coupled with the rising government initiatives are improving early diagnosis rates through expanded newborn screening programs, bolstering the market's demand.

Rising Regulatory Approvals Support Market Expansion

Increasing regulatory approvals are significantly driving the growth of the cystic fibrosis therapeutics market by facilitating the availability of innovative treatments and therapeutic solutions. In March 2025, ReCode Therapeutics, Inc. received orphan drug designation for RCT2100 from the United States Food and Drug Administration (US FDA). The investigational mRNA therapy is being developed for treating cystic fibrosis. RCT2100 is designed for delivering cystic fibrosis transmembrane conductance regulator mRNA directly to target cells in the lungs and is formulated by leveraging the company's selective organ targeting lipid nanoparticle platform.

Similarly, in February 2025, porosome reconstitution therapy for cystic fibrosis was granted orphan drug designation by the FDA. The therapy displayed increased efficacy in secretion of mucus during an analysis in which the plasma membrane of the cystic fibrosis transmembrane conductance regulator mutant cells were subjected to functional porosomes.

Additionally, the growing pipeline of clinical trials, supported by favorable regulatory environment and policies, continues to offer new opportunities for growth for the key players in the industry. Moreover, regulatory approvals often result in better reimbursement policies, boosting the accessibility of treatments more for the patient population, further bolstering the market's expansion.

Increasing Investments in Development of New Therapies Drive Market Growth

These initiatives are driving the growth of the market by fostering innovation and expanding the number of treatment options available. Investments are also accelerating research into biomarker development, personalized medicine, and gene editing technologies enabling early intervention and more effective treatments.

For instance, in January 2025, Glox Therapeutics Ltd. was awarded a grant of approximately USD 642,000 (£500,000) to advance the discovery and development of precision antibiotics that target antimicrobial-resistant lung infections in patients suffering from cystic fibrosis. Cystic fibrosis often causes thick mucus buildup in the lungs, leading to infections that become resistant to antibiotics over a period of time. Thus, addressing the urgent requirements for effective therapeutics and improving the lives of the patient population.

CFTR Modulators Account for Significant Share of the Market

The segment's growth can be attributed to the ability of these drugs to target the underlying genetic defect caused by mutations in the genes, providing a disease-modifying approach rather than addressing symptoms. This precision medicine strategy has significantly improved patient outcomes, due to improved lung functioning and increased life expectancy. Moreover, the convenience of oral administration also contributes to the popularity of CFTR modulators, allowing them to hold a significant share of the revenue.

Additionally, the rising research activities to evaluate the safety and efficacy of CFTR modulators on patients of different age groups is also supporting the segment's expansion. For instance, the La Societe Francaise de la Mucoviscidose is conducting an observational study to understand the response of CFTR modulators in patients with cystic fibrosis that are under 18. The study is estimated to conclude in July 2025.

North America Holds Major Market Share

The market's expansion in the region can be attributed to the high prevalence of cystic fibrosis in the region, increasing spendings in the healthcare sector, and strong presence of leading pharmaceutical companies. As per the estimates of the American Lung Association, approximately 40,000 people in the United States have cystic fibrosis and about one in thirty people in the country is a carrier. Moreover, research and development activities are heavily funded in North America, with major pharmaceutical corporations and research institutions collaborating to develop novel therapeutic solutions. Additionally, favorable reimbursement policies and government initiatives enhance patient access to these therapies.

Meanwhile, the Asia-Pacific is expected to witness significant growth over the forecast period due to rising investments towards the healthcare and pharmaceutical industries, improved access to innovative therapies, increasing awareness among the patient population, and growing number of research initiatives and clinical trials.

Future Market Scenario (2025 - 2032F)

The market is expected to witness significant growth in the coming years due to ongoing advancements in CFTR modulator therapies, growing awareness about the condition in developing regions, advent of various genetic editing solutions, and rising prevalence of cystic fibrosis. Additionally, increasing collaborations between biotech companies and research institutions are accelerating the development and availability of innovative solutions. Furthermore, gene therapies targeting permanent correction of cystic fibrosis transmembrane conductance regulator mutations are anticipated to enter the clinical stage over the coming years, potentially shifting the market from chronic disease management to curative approaches. Strategic partnerships, licensing deals, and public-private collaborations are also anticipated to play a crucial role in the market's expansion across the globe.

Key Players Landscape and Outlook

The key players of the market are focusing on launching new products and receiving approvals from the different regulatory bodies. For instance, in March 2025, Vertex Pharmaceuticals Incorporated's Alyftrek (deutivacaftor/tezacaftor/vanzacaftor) received approval from the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients that are six or older. Alyftrek combines enhances cystic fibrosis transmembrane regulator protein function, improving salt and water transport across cell membranes. This mechanism aids in reducing thick mucus buildup, a hallmark of cystic fibrosis, and improves lung functioning, slowing the progression of the disease. Such approvals are allowing the key players of the market to increase their revenues and improve their position in the market.

Table of Contents

1. Project Scope and Definitions

2. Research Methodology

3. Executive Summary

4. Global Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

  • 4.1. Market Size Analysis & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share Analysis & Forecast
    • 4.2.1. By Drug Class
      • 4.2.1.1. CFTR Modulators
      • 4.2.1.2. Pancreatic Enzyme Supplements
      • 4.2.1.3. Mucolytics
      • 4.2.1.4. Bronchodilators
    • 4.2.2. By Route of Administration
      • 4.2.2.1. Oral
      • 4.2.2.2. Inhaled
    • 4.2.3. By Distribution Channel
      • 4.2.3.1. Hospital Pharmacies
      • 4.2.3.2. Retail Pharmacies
      • 4.2.3.3. Online Pharmacies
    • 4.2.4. By Region
      • 4.2.4.1. North America
      • 4.2.4.2. Europe
      • 4.2.4.3. Asia-Pacific
      • 4.2.4.4. South America
      • 4.2.4.5. Middle East and Africa
    • 4.2.5. By Company Market Share Analysis (Top 5 Companies and Others - By Value, 2024)
  • 4.3. Market Map Analysis, 2024
    • 4.3.1. By Drug Class
    • 4.3.2. By Route of Administration
    • 4.3.3. By Distribution Channel
    • 4.3.4. By Region

5. North America Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

  • 5.1. Market Size Analysis & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share Analysis & Forecast
    • 5.2.1. By Drug Class
      • 5.2.1.1. CFTR Modulators
      • 5.2.1.2. Pancreatic Enzyme Supplements
      • 5.2.1.3. Mucolytics
      • 5.2.1.4. Bronchodilators
    • 5.2.2. By Route of Administration
      • 5.2.2.1. Oral
      • 5.2.2.2. Inhaled
    • 5.2.3. By Distribution Channel
      • 5.2.3.1. Hospital Pharmacies
      • 5.2.3.2. Retail Pharmacies
      • 5.2.3.3. Online Pharmacies
    • 5.2.4. By Country Share
      • 5.2.4.1. United States
      • 5.2.4.2. Canada
      • 5.2.4.3. Mexico
  • 5.3. Country Market Assessment
    • 5.3.1. United States Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F*
      • 5.3.1.1. Market Size Analysis & Forecast
        • 5.3.1.1.1. By Value
          • 5.3.1.1.1.1. Market Share Analysis & Forecast
        • 5.3.1.1.2. By Drug Class
          • 5.3.1.1.2.1. CFTR Modulators
          • 5.3.1.1.2.2. Pancreatic Enzyme Supplements
          • 5.3.1.1.2.3. Mucolytics
          • 5.3.1.1.2.4. Bronchodilators
        • 5.3.1.1.3. By Route of Administration
          • 5.3.1.1.3.1. Oral
          • 5.3.1.1.3.2. Inhaled
        • 5.3.1.1.4. By Distribution Channel
          • 5.3.1.1.4.1. Hospital Pharmacies
          • 5.3.1.1.4.2. Retail Pharmacies
          • 5.3.1.1.4.3. Online Pharmacies
    • 5.3.2. Canada
    • 5.3.3. Mexico

All segments will be provided for all regions and countries covered

6. Europe Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

  • 6.1. Germany
  • 6.2. France
  • 6.3. Italy
  • 6.4. United Kingdom
  • 6.5. Russia
  • 6.6. Netherlands
  • 6.7. Spain
  • 6.8. Turkey
  • 6.9. Poland

7. Asia-Pacific Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

  • 7.1. India
  • 7.2. China
  • 7.3. Japan
  • 7.4. Australia
  • 7.5. Vietnam
  • 7.6. South Korea
  • 7.7. Indonesia
  • 7.8. Philippines

8. South America Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

  • 8.1. Brazil
  • 8.2. Argentina

9. Middle East and Africa Cystic Fibrosis Therapeutics Market Outlook, 2018-2032F

  • 9.1. Saudi Arabia
  • 9.2. UAE
  • 9.3. South Africa

10. Demand Supply Analysis

11. Value Chain Analysis

12. Porter's Five Forces Analysis

13. PESTLE Analysis

14. Pricing Analysis

15. Market Dynamics

  • 15.1. Market Drivers
  • 15.2. Market Challenges

16. Market Trends and Developments

17. Regulatory Landscape

18. Overview of Clinical Trials

19. Case Studies

20. Competitive Landscape

  • 20.1. Competition Matrix of Top 5 Market Leaders
  • 20.2. SWOT Analysis for Top 5 Players
  • 20.3. Key Players Landscape for Top 10 Market Players
    • 20.3.1. AbbVie Inc.
      • 20.3.1.1. Company Details
      • 20.3.1.2. Key Management Personnel
      • 20.3.1.3. Products and Services
      • 20.3.1.4. Financials (As Reported)
      • 20.3.1.5. Key Market Focus and Geographical Presence
      • 20.3.1.6. Recent Developments/Collaborations/Partnerships/Mergers and Acquisition
    • 20.3.2. Gilead Sciences, Inc.
    • 20.3.3. Novartis AG
    • 20.3.4. Vertex Pharmaceuticals Incorporated
    • 20.3.5. Alaxia S.A.S.
    • 20.3.6. Teva Pharmaceutical Industries Ltd.
    • 20.3.7. Merck & Co. Inc.
    • 20.3.8. F. Hoffmann-La Roche Ltd
    • 20.3.9. Mylan NV
    • 20.3.10. AstraZeneca plc

Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.

21. Strategic Recommendations

22. About Us and Disclaimer

List of Tables

  • Table 1. Competition Matrix of Top 5 Market Leaders
  • Table 2. Mergers & Acquisitions/ Joint Ventures (If Applicable)
  • Table 3. About Us - Regions and Countries Where We Have Executed Client Projects

List of Figures

  • Figure 1. Global Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 2. Global Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 3. Global Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 4. Global Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 5. Global Cystic Fibrosis Therapeutics Market Share (%), By Region, 2018-2032F
  • Figure 6. North America Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 7. North America Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 8. North America Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 9. North America Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 10. North America Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 11. United States Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 12. United States Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 13. United States Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 14. United States Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 15. Canada Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 16. Canada Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 17. Canada Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 18. Canada Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 19. Mexico Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 20. Mexico Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 21. Mexico Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 22. Mexico Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 23. Europe Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 24. Europe Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 25. Europe Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 26. Europe Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 27. Europe Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 28. Germany Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 29. Germany Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 30. Germany Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 31. Germany Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 32. France Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 33. France Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 34. France Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 35. France Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 36. Italy Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 37. Italy Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 38. Italy Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 39. Italy Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 40. United Kingdom Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 41. United Kingdom Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 42. United Kingdom Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 43. United Kingdom Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 44. Russia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 45. Russia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 46. Russia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 47. Russia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 48. Netherlands Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 49. Netherlands Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 50. Netherlands Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 51. Netherlands Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 52. Spain Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 53. Spain Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 54. Spain Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 55. Spain Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 56. Turkey Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 57. Turkey Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 58. Turkey Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 59. Turkey Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 60. Poland Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 61. Poland Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 62. Poland Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 63. Poland Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 64. Asia-Pacific Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 65. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 66. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 67. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 68. Asia-Pacific Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 69. India Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 70. India Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 71. India Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 72. India Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 73. China Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 74. China Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 75. China Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 76. China Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 77. Japan Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 78. Japan Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 79. Japan Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 80. Japan Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 81. Australia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 82. Australia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 83. Australia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 84. Australia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 85. Vietnam Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 86. Vietnam Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 87. Vietnam Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 88. Vietnam Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 89. South Korea Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 90. South Korea Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 91. South Korea Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 92. South Korea Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 93. Indonesia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 94. Indonesia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 95. Indonesia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 96. Indonesia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 97. Philippines Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 98. Philippines Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 99. Philippines Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 100. Philippines Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 101. South America Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 102. South America Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 103. South America Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 104. South America Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 105. South America Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 106. Brazil Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 107. Brazil Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 108. Brazil Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 109. Brazil Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 110. Argentina Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 111. Argentina Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 112. Argentina Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 113. Argentina Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 114. Middle East & Africa Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 115. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 116. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 117. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 118. Middle East & Africa Cystic Fibrosis Therapeutics Market Share (%), By Country, 2018-2032F
  • Figure 119. Saudi Arabia Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 120. Saudi Arabia Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 121. Saudi Arabia Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 122. Saudi Arabia Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 123. UAE Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 124. UAE Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 125. UAE Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 126. UAE Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 127. South Africa Cystic Fibrosis Therapeutics Market, By Value, In USD Billion, 2018-2032F
  • Figure 128. South Africa Cystic Fibrosis Therapeutics Market Share (%), By Drug Class, 2018-2032F
  • Figure 129. South Africa Cystic Fibrosis Therapeutics Market Share (%), By Route of Administration, 2018-2032F
  • Figure 130. South Africa Cystic Fibrosis Therapeutics Market Share (%), By Distribution Channel, 2018-2032F
  • Figure 131. By Drug Class Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 132. By Route of Administration Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 133. By Distribution Channel Map-Market Size (USD Billion) & Growth Rate (%), 2024
  • Figure 134. By Region Map-Market Size (USD Billion) & Growth Rate (%), 2024